Lyra Therapeutics (LYRA) Asset Writedowns and Impairment (2023 - 2024)
Quarterly Asset Writedowns and Impairment rose 21900.0% to $1.8 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Sep 2025, down 6.93% year-over-year, with the annual reading at $1.9 million for FY2024, 18.75% up from the prior year.
Lyra Therapeutics' Asset Writedowns and Impairment history spans 2 years, with the latest figure at $1.8 million for Q4 2024.
- Asset Writedowns and Impairment came in at $1.8 million for Q4 2024, down from $1.9 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $1.9 million in Q2 2024 to a low of $8000.0 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Lyra Therapeutics | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.76 Mn |
| Dec 31, 2024 | 1.76 Mn |
| Jun 30, 2024 | 1.88 Mn |
| Jun 30, 2024 | 1.88 Mn |
| Dec 31, 2023 | 8,000.00 |
| Dec 31, 2023 | 8,000.00 |
| Jun 30, 2023 | 1.59 Mn |
| Jun 30, 2023 | 1.59 Mn |